GlassScriptPhysician profile
Yeswanth Attoti
NPI 1972095198
$4,871.11
in general payments reported to CMS, 2019-2025
24 companies · $1,479 in 2025
The $1,479 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $19.63 · 2021: $197 · 2022: $736 · 2023: $923 · 2024: $1,516 · 2025: $1,479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,898 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.29 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,007.80 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $915.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $388.03 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $293.55 | 2021-2025 | Jardiance |
| Amgen INC. | $280.68 | 2022-2025 | Repatha, Otezla, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.21 | 2024-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $263.90 | 2022-2025 | |
| Abbvie INC. | $238.68 | 2022-2025 | Ubrelvy |
| Exact Sciences Corporation | $182.04 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $177.35 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Esperion Therapeutics, INC. | $164.67 | 2021-2025 | Nexletol |
| Pfizer INC. | $151.79 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $108.40 | 2022-2024 | |
| Astellas Pharma US INC | $83.96 | 2023-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $65.04 | 2024-2025 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $47.89 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $41.96 | 2023-2024 | Rexulti |
| Tactile Systems Technology INC | $41.57 | 2025 | Nimbl, Flexitouch Plus |
| Abbott Laboratories | $35.31 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $34.74 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $19.68 | 2023 | Xarelto |
| Mallinckrodt Hospital Products INC. | $19.63 | 2020 | |
| Eisai INC. | $18.20 | 2021 | |
| Philips North America LLC | $17.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeswanth Attoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.